CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus.
- DOI
- 10.1007/s11033-026-12771-1
- Published
- 2026 Sep 18
- Container
- Molecular biology reports
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11033-026-12771-1,
title = {CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus.},
author = {Islam MN and Islam MM and Feng H and Bellah SF and Zaman Miah MM and Hossain MS},
year = {2026},
journal = {Molecular biology reports},
doi = {10.1007/s11033-026-12771-1},
url = {https://doi.org/10.1007/s11033-026-12771-1}
}RIS
TY - JOUR TI - CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus. AU - Islam MN AU - Islam MM AU - Feng H AU - Bellah SF AU - Zaman Miah MM AU - Hossain MS PY - 2026 JO - Molecular biology reports DO - 10.1007/s11033-026-12771-1 UR - https://doi.org/10.1007/s11033-026-12771-1 ER -
APA
MN, I., MM, I., H, F., SF, B., MM, Z. M., & MS, H. (2026). CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus.. Molecular biology reports. https://doi.org/10.1007/s11033-026-12771-1
Source records
- pubmed · retrieved 2026-09-25T11:46:10.935Z